A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study) (BALANCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02159079 |
|
Recruitment Status :
Completed
First Posted : June 9, 2014
Results First Posted : November 1, 2019
Last Update Posted : November 1, 2019
|
Sponsor:
Vanderbilt University
Information provided by (Responsible Party):
Matthew Semler, Vanderbilt University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Sepsis is a common inflammatory response to infection characterized by hypovolemia and vasodilation for which early administration of intravenous fluids has been suggested to improve outcomes. The ideal fluid balance following initial resuscitation is unclear. Septic patients treated in the intensive care unit commonly receive significant volumes of intravenous fluids with resultant positive fluid balance for up to a week after their initial resuscitation. Observational studies have associated fluid receipt and positive fluid balance in patients with severe sepsis and septic shock with increased mortality but are inherently limited by indication bias. In order to determine the optimal approach to fluid management following resuscitation in patients with severe sepsis and septic shock, a randomized controlled trial is needed. The primary hypothesis of this study is that, compared to usual care, a conservative approach to fluid management after resuscitation in patients with sepsis and cardiopulmonary dysfunction will increase intensive care unit free days.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Sepsis | Other: Conservative Fluid Management Strategy | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 30 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II/III Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction |
| Study Start Date : | July 2014 |
| Actual Primary Completion Date : | February 2016 |
| Actual Study Completion Date : | April 2016 |
| Arm | Intervention/treatment |
|---|---|
|
No Intervention: Usual Care
Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
|
|
|
Experimental: Conservative Fluid Management Strategy
For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
|
Other: Conservative Fluid Management Strategy
For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event. |
Primary Outcome Measures :
- ICU-free Days to 14 Days After Enrollment [ Time Frame: 14 days ]The primary outcome will be the number of ICU-free days to day 14 (defined as the number days alive and outside of the intensive care unit in the first 14 days after enrollment).
Secondary Outcome Measures :
- Ventilator-free Days to Day 14 [ Time Frame: 14 days ]A secondary outcome will be the number of ventilator-free days (defined as the number of days alive and breathing unassisted after the final achievement of unassisted breathing before day 14)
- In-hospital Mortality to Day 14 [ Time Frame: 14 days ]A secondary outcome will be in-hospital mortality to day 14 (defined as the incidence of mortality prior to hospital discharge within 14 days after enrollment).
- Renal Replacement Therapy-free Days to Day 14 [ Time Frame: 14 days ]Renal replacement therapy-free days to day 14 (defined as the number of days alive and free of renal replacement therapy from the last receipt of renal replacement therapy after enrollment to study day 14)
- Highest Stage of Acute Kidney Injury [ Time Frame: 28 days ]Highest stage of acute kidney injury as defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria Stage 0 (no acute kidney injury) Stage 1 Serum creatinine 1.5-1.9 times baseline or ≥0.3 mg/dl (≥26.5 mmol/l) increase or Urine output <0.5 ml/kg/h for 6-12 hours Stage 2 Serum creatinine 2.0-2.9 times baseline or <0.5 ml/kg/h for ≥12 hours Stage 3 Serum creatinine 3.0 times baseline or Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 mmol/l) or Initiation of renal replacement therapy or in patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m² or Urine output <0.3 ml/kg/h for ≥24 hours or anuria for ≥12 hours
- Highest Plasma Creatinine Between Enrollment and 28 Days After Enrollment [ Time Frame: 28 days ]Highest plasma creatinine (mg/dL) between enrollment and 28 days after enrollment, censored at hospital discharge
- Receipt of Renal Replacement Therapy [ Time Frame: 28 days ]receipt of renal replacement therapy between enrollment and the first of 28 days or hospital discharge
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- ICU patients
- Adults
- Sepsis as defined by at least two systemic inflammatory response syndrome criteria and receipt of antimicrobial therapy
- Cardiopulmonary dysfunction as defined shock or respiratory failure
Exclusion Criteria:
- Inability to obtain consent
- Greater than 48 hours since inclusion criteria initially met
- Allergy to furosemide AND bumetanide
- Rhabdomyolysis with creatinine kinase > 5000 U/L
- Hypercalcemia with calcium >11 mg/dL
- Diabetic Ketoacidosis requiring continuous insulin infusion
- Tumor Lysis Syndrome diagnosed clinically
- Pancreatitis diagnosed clinically
- Chronic Hypoxic Respiratory Failure with Home Oxygen Use of FiO2≥0.3
- Chronic ventilator dependence
- cervical spinal cord injury at level C5 or higher
- amyotrophic lateral sclerosis
- Guillain-Barré Syndrome
- myasthenia gravis
- Renal failure requiring renal replacement therapy
- Burns >20% of body surface area
- Pregnant
- Preexisting pulmonary hypertension with PAPmean>40 on RHC
- Severe chronic liver disease with Childs-Pugh Score >11
- Moribund and not expected to survive an additional 24 hours
- Actively withdrawing life support or transitioning to comfort measures only
- Unwillingness of treating physician to employ conservative fluid strategy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02159079
Locations
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
Sponsors and Collaborators
Vanderbilt University
Investigators
| Principal Investigator: | Matthew W. Semler, M.D. | Vanderbilt University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Matthew Semler, Fellow in Pulmonary and Critical Care Medicine, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT02159079 |
| Other Study ID Numbers: |
140582 |
| First Posted: | June 9, 2014 Key Record Dates |
| Results First Posted: | November 1, 2019 |
| Last Update Posted: | November 1, 2019 |
| Last Verified: | October 2019 |
Keywords provided by Matthew Semler, Vanderbilt University:
|
Sepsis Severe Sepsis Septic Shock |
Conservative Fluid Management Fluid Balance Fluid Restriction |
Additional relevant MeSH terms:
|
Sepsis Toxemia Infections |
Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |